First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.
作者信息
Dziewięcka Ewa, Winiarczyk Mateusz, Gliniak Matylda, Kaciczak Monika, Wiśniowska-Śmiałek Sylwia, Karabinowska Aleksandra, Holcman Katarzyna, Kostkiewicz Magdalena, Hlawaty Marta, Leśniak-Sobelga Agata, Podolec Piotr, Rubiś Paweł
机构信息
Collegium Medicum of Jagiellonian University, Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, ul.Prądnicka 80, 31-202 Cracow, Poland.
agiellonian University Collegium Medicum, Students' Scientific Group at Department of Cardiac and Vascular Diseases, John Paul II Hospital, Prądnicka Street 80, 31-202 Kraków, Poland.
出版信息
Cardiol J. 2020;27(5):639-641. doi: 10.5603/CJ.a2020.0100. Epub 2020 Aug 13.
Abstract
摘要
相似文献
1
First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.波兰心血管疾病患者使用钠-葡萄糖协同转运蛋白2抑制剂的首次经验。
Cardiol J. 2020;27(5):639-641. doi: 10.5603/CJ.a2020.0100. Epub 2020 Aug 13.
2
Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline.评估钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者新发阻塞性睡眠呼吸暂停风险的影响的荟萃分析，无论基线时是否患有心血管疾病。
Am J Cardiol. 2022 Sep 15;179:116-117. doi: 10.1016/j.amjcard.2022.06.022. Epub 2022 Jul 20.
3
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.评估钠-葡萄糖协同转运蛋白2抑制剂对慢性阻塞性肺疾病患者心血管疗效的荟萃分析
Am J Cardiol. 2022 Jul 1;174:188-189. doi: 10.1016/j.amjcard.2022.04.003. Epub 2022 May 9.
4
Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer?钠-葡萄糖协同转运蛋白2抑制剂、肠道微生物群与动脉粥样硬化性心血管疾病：又一座有待攻克的高峰？
Pharmacol Res. 2023 Jan;187:106619. doi: 10.1016/j.phrs.2022.106619. Epub 2022 Dec 16.
5
Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.在无心血管和肾脏疾病的2型糖尿病患者中，钠-葡萄糖协同转运蛋白2抑制剂与二肽基肽酶-4抑制剂的心脏肾脏获益比较
Diabetes Obes Metab. 2022 Mar;24(3):575-577. doi: 10.1111/dom.14588. Epub 2021 Nov 15.
6
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.在标志性心血管和肾脏结局试验中评估钠-葡萄糖协同转运蛋白2抑制剂导致截肢风险的最新荟萃分析。
Diabetes Obes Metab. 2021 Apr;23(4):1063-1065. doi: 10.1111/dom.14297. Epub 2020 Dec 29.
7
Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂联合治疗：前景可期，但我们是否应关注其他指标？
Int J Cardiol. 2021 Jan 15;323:259. doi: 10.1016/j.ijcard.2020.08.049. Epub 2020 Aug 15.
8
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?钠-葡萄糖协同转运蛋白2抑制剂、心血管结局及性别影响：类效应还是统计学上的偶然？
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):347. doi: 10.1016/j.dsx.2020.04.010. Epub 2020 Apr 11.
9
Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs.钠-葡萄糖协同转运蛋白2抑制剂：了解患者与药物。
Hong Kong Med J. 2019 Aug;25(4):268-270. doi: 10.12809/hkmj195089.
10
Sodium-glucose co-transporter type-2 inhibitors: is the message getting through? A reply.
Anaesthesia. 2019 May;74(5):680. doi: 10.1111/anae.14642.
本文引用的文献
1
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.达格列净用于射血分数降低的心力衰竭患者。回复。
N Engl J Med. 2020 Mar 5;382(10):973. doi: 10.1056/NEJMc1917241.
2
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.2019年欧洲心脏病学会（ESC）与欧洲糖尿病研究协会（EASD）合作制定的糖尿病、糖尿病前期和心血管疾病指南。
Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
3
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.达格列净与2型糖尿病患者的心血管结局。回复
N Engl J Med. 2019 May 9;380(19):1881-1882. doi: 10.1056/NEJMc1902837.
4
Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.心力衰竭住院患者合并症的趋势：来自 Get With The Guidelines-Heart Failure 注册研究的见解。
Circ Heart Fail. 2018 Jun;11(6):e004646. doi: 10.1161/CIRCHEARTFAILURE.117.004646.
5
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.恩格列净治疗心血管高危2型糖尿病患者的心力衰竭结局：EMPA-REG OUTCOME®试验结果
Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.
6
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
7
Association of Cardiometabolic Multimorbidity With Mortality.心脏代谢多重疾病与死亡率的关联
JAMA. 2015 Jul 7;314(1):52-60. doi: 10.1001/jama.2015.7008.
8
9
10
Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.已知或新检测出的糖尿病（而非血糖调节受损）对冠心病患者的1年预后有负面影响：来自欧洲心脏调查糖尿病与心脏项目的报告
Eur Heart J. 2006 Dec;27(24):2969-74. doi: 10.1093/eurheartj/ehl363. Epub 2006 Nov 7.
Zotero 插件